You would be surprised to find out just how many questions are answered by the analysis of the relationship that emerges between generic competition and drug prices. For manufacturers and…
Valuing pharma companies isn’t the same as valuing non-pharma companies, for several reasons. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of…
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about the sustainability and profitability of major generics companies. But some…
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today Volume 23, Issue 1, January…
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of datasets with the help of which companies are able to…
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
Considering switching to DrugPatentWatch? See why others have come to us. DrugPatentWatch Alternatives
Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements
0
This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under a Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) Abstract A 505(b)(2)…
Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.